# Sorafenib and FOLFIRI Regimen in 2nd Colorectal Cancer (CRC) After Failure of Oxaliplatin Treatment

> **NCT00839111** · PHASE2 · UNKNOWN · sponsor: **Fudan University** · enrollment: 43 (estimated)

## Conditions studied

- Colorectal Neoplasms

## Interventions

- **DRUG:** sorafenib
- **DRUG:** FOLFIRI

## Key facts

- **NCT ID:** NCT00839111
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2008-11
- **Primary completion:** 2010-11
- **Final completion:** 2010-11
- **Target enrollment:** 43 (ESTIMATED)
- **Last updated:** 2010-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00839111

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00839111, "Sorafenib and FOLFIRI Regimen in 2nd Colorectal Cancer (CRC) After Failure of Oxaliplatin Treatment". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00839111. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*